MangoRx initiates efficacy studies on patented respiratory illness prevention

Mangoceuticals announces the initiation of efficacy studies on its patented respiratory illness prevention technology in collaboration with Vipragen Biosciences and IntraMont Technologies. Notably, these trials have been pre-funded, ensuring that the Company does not need to raise any additional capital for the completion of these studies, which are anticipated to be concluded in the earlier part of the 3rd quarter. The recently acquired patented technology by MangoRx is designed to reduce the incidence of respiratory illnesses, including, but not limited to, H1N1 variants, Avian Flu, the common cold, Coronavirus and others. The studies are set to commence within the next few weeks with results anticipated to be concluded in the earlier part of the 3rd quarter. These include animal studies to quantify the prophylactic performance of the technology against select viruses and viral strains. The composition being tested contains a very select tannin and zinc gluconate as its primary active ingredients.